Recent research indicates that children diagnosed with Autism Spectrum Disorder (ASD) have notably lower serum levels of 25-hydroxyvitamin D compared to their neurotypical counterparts. Furthermore, early-life vitamin D deficiency has been identified as a significant risk factor for the development of ASD.
Read More
Vitamin D is believed to play a crucial role in neurodevelopment through various mechanisms, including anti-inflammatory effects, promotion of neurotrophin production, and regulation of neurotransmitter synthesis, particularly serotonin. These functions may contribute positively to symptoms associated with ASD.
High-dose vitamin D supplementation has been linked to improvements in specific behaviors associated with ASD, such as repetitive behaviors. However, the effects on a broader spectrum of symptoms have been less consistent.
Pharmacists are advised to evaluate patients with ASD for potential vitamin D deficiency and consider supplementation as part of a comprehensive treatment strategy, collaborating closely with healthcare providers.
An umbrella review encompassing nine meta-analyses highlighted the lower serum 25-hydroxyvitamin D levels in children with ASD, reinforcing the connection between vitamin D deficiency and the risk of developing the disorder. Moreover, research shows that vitamin D supports neurodevelopment through its role in neuroprotection and the reduction of factors linked to ASD pathology.
A randomized controlled trial tested high-dose vitamin D (300 IU/kg per day, up to 5000 IU per day) in children with ASD, revealing significant improvements in assessment scores for autism symptoms, including eye contact and attention, after four months.
Despite these promising findings, existing evidence is not entirely conclusive. While some studies report beneficial effects, variability in dosing, trial lengths, and sample sizes highlight the need for larger, well-structured trials to better determine optimal dosing, timing, and long-term safety of vitamin D therapy.
In practice, pharmacists should screen ASD patients for vitamin D deficiency, particularly those with limited sun exposure or restrictive diets, and recommend tests to measure serum 25-hydroxyvitamin D levels. Maintaining levels above 40 ng/mL may correlate with improved outcomes.
Vitamin D supplementation is emerging as a safe and cost-effective intervention for ASD that may reduce risk and enhance certain behavioral symptoms. Pharmacists can play a pivotal role in implementing evidence-based practices while continuing to monitor advancements in this area.